Related Experiment Videos
Tumour angiogenesis factor in urological cancers
British Journal of Urology
|October 1, 1984
Summary
Tumour angiogenesis factor (TAF) was detected in most urological cancer tissues and urine samples. Radioimmunoassay (RIA) of urine for TAF shows potential as a non-invasive screening test for bladder cancer.
Area of Science:
- Uro-oncology
- Biomarker Discovery
- Cancer Diagnostics
Background:
- Tumour angiogenesis is crucial for cancer growth and metastasis.
- Identifying reliable biomarkers for early cancer detection remains a significant challenge in urology.
Purpose of the Study:
- To investigate the presence and diagnostic potential of tumour angiogenesis factor (TAF) in urological cancers.
- To evaluate radioimmunoassay (RIA) as a method for detecting TAF in patient samples.
Main Methods:
- Bioassay and radioimmunoassay (RIA) were employed to detect TAF.
- Analysis was performed on tissue and urine samples from patients with various urological cancers and healthy controls.
Main Results:
- TAF was detected in the majority of tumour tissues and urine samples from cancer patients.
- TAF was notably absent in control samples, indicating specificity.
- RIA demonstrated TAF presence in urine, correlating with tumour presence.
Conclusions:
- TAF is a prevalent factor in urological tumours.
- Urine TAF detection via RIA presents a promising avenue for non-invasive bladder cancer screening.
- Further validation of RIA for TAF in urine could enhance early detection strategies.